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As the era of precision and personalized medicine is gaining 
exponential positive gain in the field of medicine, there is a 
positive shift towards a more evidence-based patient care 
approach for patients with hepatological diseases. One fac-
tor that is crucial in any physician’s decision-making efforts 
involves the application of novel innovative approaches that 
can enhance predicting survival outcome. Acute-on-chronic 
liver failure (ACLF) is a perfect example of how liver can 
rapidly deteriorate, and the hepatitis B virus (HBV) is one 
crucial culprit. Patients can experience organ failure that 
leads to their mortality, and in this article the authors clearly 
described the use of backward stepwise logistic regression 
(LR) and classification and regression tree (CART) analysis 
to derive two predictive models and then compared them 
with the model of end-stage liver disease (MELD) score for 
novel prognostic models of the 180-day outcome for pa-
tients with HBV-ACLF.
This innovative study showed the novel predictive models 
to be superior to MELD score, providing Hepatologists and 
Gastroenterologists with a new guiding technique in their 
evidence-based patient-centered care approach for their 
clinical treatment decision-making. Of note, one of the lead-
ing causes of chronic liver failure in Asia is HBV1 and the 
current leading therapeutical intervention for cure is liver 
transplantation (LT).2–4
However, due to decline of health of patients with ACLF, 
some of the patients become delisted from the organ trans-
plantation list because they are not well enough to undergo 
LT. Currently, MELD score is the most used for patients on 
the LT list, although several other scoring modalities are 
available.5 Current and recent advancements in Hepatol-
ogy generated the finding for HBV-ACLF having a window 
of 30 to 90 days, with respect to the scoring system used. 
In the article of interest, the authors introduced a predic-
tive module of 180-day outcome for patients based upon 
multiple variables that are not currently used in the MELD 
score. Also, there are other scoring systems that have been 
introduced for HBV-ACLF recently; although, the authors 
created a CART system scoring that is easier for the cli-
nician to interpret and, in turn, for the patient to receive 
the paramount care they deserve. Ultimately, the research 
demonstrated that both LR and the CART model appeared 
to perform better than the MELD score.
There are, however, some factors and limitations within 
the study (as properly mentioned in the article), ranging 
from not having a mid-data report and not having a larger 
cohort for studying their novel scoring models. I believe if 
a consensus can be developed by having multiple LT cent-
ers around the globe adapt this novel scoring module, we 
can achieve a better understanding and more precise scor-
ing system developed for patients with HBV-ACLF requiring 
LT. These novel models which the authors have described 
and investigated may be helpful for Transplant Hepatolo-
gists, Gastroenterologists and Health Care teams who need 
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